BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 4855753)

  • 1. Properdin factor D: characterization of its active site and isolation of the precursor form.
    Fearon DT; Austen KF; Ruddy S
    J Exp Med; 1974 Feb; 139(2):355-66. PubMed ID: 4855753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properdin: initiation of alternative complement pathway.
    Fearon DT; Austen KF
    Proc Natl Acad Sci U S A; 1975 Aug; 72(8):3220-4. PubMed ID: 1059108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.
    Fearon DT; Austen KF
    J Exp Med; 1975 Oct; 142(4):856-63. PubMed ID: 1185108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
    Medicus RG; Götze O; Müller-Eberhard HJ
    J Exp Med; 1976 Oct; 144(4):1076-93. PubMed ID: 978134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formation in the presence of C3 nephritic factor (C3NeF) of an alternative pathway C3 convertase containing uncleaved B.
    Daha MR; Fearon DT; Austen KF
    Immunology; 1976 Nov; 31(5):789-96. PubMed ID: 992711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Properdin factor D. II. Activation to D by properdin.
    Fearon DT; Austen KF; Ruddy S
    J Exp Med; 1974 Aug; 140(2):426-36. PubMed ID: 4211020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.
    Fearon DT; Austen KF
    Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1683-7. PubMed ID: 266208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.
    Ruddy S; Austen KF; Goetzl EJ
    J Clin Invest; 1975 Mar; 55(3):587-92. PubMed ID: 1167871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement.
    Fearon DT; Austen KF; Ruddy S
    J Exp Med; 1973 Dec; 138(6):1305-13. PubMed ID: 4202731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
    Fearon DT; Austen KF
    J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation and composition of the C3 activating enzyme complex of the properdin system. Sequential assembly of its components on solid-phase trypsin-agarose.
    Vogt W; Schmidt G; Dieminger L; Lynen R
    Z Immunitatsforsch Exp Klin Immunol; 1975 Jul; 149(5):440-55. PubMed ID: 126576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
    Whaley K; Schur PH; Ruddy S
    J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cofactors required by C3 nephritic factor to generate a C3 convertase in vitro.
    Amos N; Sissons JG; Girard JF; Lachmann PJ; Peters DK
    Clin Exp Immunol; 1976 Jun; 24(3):474-82. PubMed ID: 939051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A molecular concept of the properdin pathway.
    Medicus RG; Schreiber RD; Götze O; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1976 Feb; 73(2):612-6. PubMed ID: 54923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.
    Schreiber RD; Medicus RG; Gïtze O; Müller-Eberhard HJ
    J Exp Med; 1975 Sep; 142(3):760-72. PubMed ID: 1165475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathways.
    Medicus RG; Götze O; Müller-Eberhard HJ
    Scand J Immunol; 1976; 5(9):1049-55. PubMed ID: 1006167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.
    Schreiber RD; Götze O; Müller-Eberhard HJ
    J Exp Med; 1976 Oct; 144(4):1062-75. PubMed ID: 62010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formation of prethrombin-E, thrombin, and thrombin-E and their inhibition with antithrombin and enzyme inhibitors.
    Seegers WH; Andary TJ
    Thromb Res; 1974 Jun; 4(6):869-74. PubMed ID: 4858456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.